Rebeccamycin Analog in Treating Patients With Advanced Kidney Cancer

Phase 2

Completed

• Conditions: Kidney Cancer

• Registration Number: NCT00005027
• Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of rebeccamycin analog in treating patients who have advanced kidney cancer.

Detailed Description

OBJECTIVES:

* Determine the response rate of patients with advanced renal cell carcinoma when treated with rebeccamycin analogue.

* Assess the quantitative and qualitative toxicities associated with this drug in this patient population.

OUTLINE: Patients receive rebeccamycin analogue IV over 30-60 minutes daily for 5 days. Treatment continues every 21 days in the absence of disease progression or unacceptable toxicity.

PROJECTED ACCRUAL: A total of 23-44 patients will be accrued for this study within 9-18 months.

Study Timeline

• Study First Submitted: 2000-04-06
• Study Start: 2000-06
• Study First Submitted QC: 2003-08-07
• Study First Posted: 2003-08-08
• Primary Completion: 2005-03
• Study Completion: 2005-03
• Status Verified: 2013-04
• Last Update Submitted: 2013-04-03
• Last Update Posted: 2013-04-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Barbara Ann Karmanos Cancer Institute; 🇺🇸 Detroit, Michigan, United States